CEL-SCI Corporation Reports Reduced Net Loss and Financial Challenges in Latest 10-Q Filing

CEL-SCI Corporation has reported significant financial developments in its latest 10-Q filing for the six months ending March 31, 2026. The company recorded a net loss of approximately $10.9 million, a decrease from a net loss of $13.6 million during the same period in 2025. This translates to a net loss per share of $1.35, compared to $5.47 in the previous year, reflecting a substantial reduction in losses despite the absence of revenue generation. Total operating expenses for the period were approximately $10.7 million, down from $13.3 million in the prior year, primarily due to reduced research and development costs.

In terms of assets, CEL-SCI's total assets decreased to $17.7 million as of March 31, 2026, down from $28.2 million at the end of September 2025. This decline was largely driven by a significant reduction in cash and cash equivalents, which fell to $1.9 million from $10.9 million. The company's liabilities also decreased, totaling $10.8 million compared to $12.2 million in the previous period. The reduction in both assets and liabilities indicates a tightening of the company's financial position, which has raised concerns about its ability to continue as a going concern.

Strategically, CEL-SCI is focused on advancing its lead investigational therapy, Multikine, which is currently in Phase 3 clinical trials for the treatment of head and neck cancer. The company has completed a bias analysis for the target population and is preparing for a confirmatory registration study, which is expected to enroll 212 patients. The company aims to leverage the promising survival data from previous trials, which indicated a 73% survival rate for patients treated with Multikine compared to 45% for those who did not receive the treatment.

Operationally, CEL-SCI has made notable changes, including a reduction in employee headcount and a decrease in clinical trial expenses, which fell to $47,000 from $471,000 year-over-year. The company has also seen a decrease in general and administrative expenses, which dropped by 33% to approximately $3.3 million. These operational adjustments reflect CEL-SCI's efforts to streamline costs in light of its ongoing financial challenges.

Looking ahead, CEL-SCI acknowledges the need for additional capital to fund its operations and clinical trials, particularly the upcoming confirmatory study for Multikine, which is estimated to cost between $30 million and $35 million. The company has expressed substantial doubt about its ability to continue as a going concern without securing further financing. Despite these challenges, CEL-SCI remains optimistic about the potential of Multikine and its strategic direction, aiming to secure the necessary funding to advance its clinical programs and achieve regulatory approvals.